Baidu
map

Cancer:循环代谢物有望成为癌症检测新标记

2017-06-29 cailingrui MedSci原创

结肠腺瘤息肉(PLPs)患者很有很大可能性会发展为结直肠癌(CRC)。然而,用于筛查、监督和早期检测结肠腺瘤息肉和结直肠癌的有效方法和生物标志物,对我们来说仍然是一项巨大的挑战。此项研究旨在通过对癌症不同发展阶段的人类血清样本进行代谢组学分析,进而探明结直肠癌的有效生物标志物。

结肠腺瘤息肉(PLPs)患者很有很大可能性会发展为结直肠癌(CRC)。然而,用于筛查、监督和早期检测结肠腺瘤息肉和结直肠癌的有效方法和生物标志物,对我们来说仍然是一项巨大的挑战。此项研究旨在通过对癌症不同发展阶段的人类血清样本进行代谢组学分析,进而探明结直肠癌的有效生物标志物。 

研究采用Metabolon平台,对30个结直肠癌患者、30个结肠腺瘤息肉患者和30个对照进行了代谢组学分析。在随后的一组验证试验中,采用液相色谱-串联质谱法,在另外一组由50个结直肠癌患者、50个结肠腺瘤息肉患者和50个对照组成的被试中,对主要代谢物进行了靶标确认。并用多元变量逻辑回归方法对结肠腺瘤息肉和结直肠癌之间的相关性做出了评估。 

在开始的阶段,检测到404种血清代谢物,其中50种在结直肠癌患者、结肠腺瘤息肉患者和对照中表现出显著差异(P<0.05)。随后3种重要的代谢物得到了验证,分别是黄嘌呤、次黄嘌呤和D-甘露糖。与对照组相比,结直肠癌和结肠腺瘤息肉患者中黄嘌呤和次黄嘌呤代谢水平较低,D-甘露糖代谢水平较高。对代谢途径的进一步分析,揭示了尿素循环和咖啡因代谢在结直肠癌和结肠腺瘤息肉患病风险中的关键作用。此外,更发现了顶级代谢物与吸烟的联合效应以及与BMI的显著互作。对次黄嘌呤和黄嘌呤水平比例的分析更表明了他们在结直肠癌发展进程中的相关性。 

此项研究结果表明,循环代谢物作为新的结直肠癌早期检测标志物的潜在可能。

原始出处:
本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1765452, encodeId=71971e654523d, content=<a href='/topic/show?id=dee3e139503' target=_blank style='color:#2F92EE;'>#癌症检测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71395, encryptionId=dee3e139503, topicName=癌症检测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Thu Aug 24 03:04:00 CST 2017, time=2017-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1659953, encodeId=146d16599536a, content=<a href='/topic/show?id=24e82545262' target=_blank style='color:#2F92EE;'>#代谢物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25452, encryptionId=24e82545262, topicName=代谢物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c1225086772, createdName=旅苦化文_216, createdTime=Fri Sep 29 06:04:00 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216724, encodeId=a3aa216e24a0, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Thu Jun 29 16:33:58 CST 2017, time=2017-06-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1765452, encodeId=71971e654523d, content=<a href='/topic/show?id=dee3e139503' target=_blank style='color:#2F92EE;'>#癌症检测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71395, encryptionId=dee3e139503, topicName=癌症检测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Thu Aug 24 03:04:00 CST 2017, time=2017-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1659953, encodeId=146d16599536a, content=<a href='/topic/show?id=24e82545262' target=_blank style='color:#2F92EE;'>#代谢物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25452, encryptionId=24e82545262, topicName=代谢物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c1225086772, createdName=旅苦化文_216, createdTime=Fri Sep 29 06:04:00 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216724, encodeId=a3aa216e24a0, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Thu Jun 29 16:33:58 CST 2017, time=2017-06-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1765452, encodeId=71971e654523d, content=<a href='/topic/show?id=dee3e139503' target=_blank style='color:#2F92EE;'>#癌症检测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71395, encryptionId=dee3e139503, topicName=癌症检测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Thu Aug 24 03:04:00 CST 2017, time=2017-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1659953, encodeId=146d16599536a, content=<a href='/topic/show?id=24e82545262' target=_blank style='color:#2F92EE;'>#代谢物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25452, encryptionId=24e82545262, topicName=代谢物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c1225086772, createdName=旅苦化文_216, createdTime=Fri Sep 29 06:04:00 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216724, encodeId=a3aa216e24a0, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Thu Jun 29 16:33:58 CST 2017, time=2017-06-29, status=1, ipAttribution=)]
    2017-06-29 luominglian113

    学习了,谢谢分享

    0

Baidu
map
Baidu
map
Baidu
map